Melanotan II (MT-II)

Melanotan II operates through non-selective agonism of the melanocortin receptor (MCR) family — a group of G-protein coupled receptors (Gαs-coupled) that, upon activation, stimulate adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and activating the protein kinase A (PKA) signaling cascade across diverse tissue types. The pharmacological breadth of Melanotan II’s effects is a direct consequence of its engagement with four of the five MCR subtypes, each mediating a distinct set of physiological responses.

MC1R: Melanogenesis and Skin Pigmentation

The most clinically prominent and initially intended effect of Melanotan II is its activation of the melanocortin-1 receptor (MC1R), expressed on melanocytes in the skin and hair follicles:

• MC1R agonism in melanocytes activates the cAMP/PKA pathway, upregulating the transcription factor MITF (microphthalmia-associated transcription factor), which drives expression of melanogenic enzymes — primarily tyrosinase — resulting in increased eumelanin synthesis
• Eumelanin (brown-black pigment) accumulation in the epidermis produces skin darkening (tanning) independent of UV radiation — the founding rationale for Melanotan II’s development
• The University of Arizona Phase 1 clinical trial (1996) demonstrated that five low subcutaneous doses administered every other day produced visually apparent tanning in human subjects — the first proof-of-concept evidence in humans
• Melanotan II also causes rapid darkening and proliferation of pre-existing melanocytic nevi (moles) via MC1R-driven melanocyte stimulation — a clinically significant safety concern that distinguishes it from afamelanotide’s more selective MC1R profile
• The non-selective receptor engagement of Melanotan II — as compared to afamelanotide (Melanotan I), which is more MC1R-selective — is the fundamental reason its tanning-indication development was halted; the additional receptor activations produce adverse effects not seen with the more selective analogue

MC4R: Sexual Function, Appetite Suppression, and Energy Balance

MC4R agonism is responsible for Melanotan II’s two most widely recognized off-label uses — sexual arousal/erectile function and appetite suppression — and represents the receptor subtype of greatest clinical and pharmacological relevance beyond pigmentation:

• Penile erection and sexual arousal: MC4R is expressed in hypothalamic nuclei involved in sexual behavior. Melanotan II produces penile erection in men independent of sexual stimulation, through a central MC4R-mediated mechanism distinct from PDE5 inhibitors (sildenafil). University of Arizona clinical trials demonstrated erection in 17 of 20 men with erectile dysfunction in the absence of stimulation, with mean tip rigidity >80% sustained for ~41 minutes
• Bremelanotide (PT-141) — a direct metabolite of Melanotan II formed by hydrolysis of the N-terminal acetyl group — was subsequently developed from Melanotan II’s sexual function profile and ultimately received FDA approval in 2019 (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women; this represents the only FDA-approved therapeutic to emerge from the Melanotan II pharmacological lineage
• Appetite suppression: MC4R activation in hypothalamic circuits (particularly the paraventricular nucleus) produces robust, dose-dependent anorexia in preclinical models; however, tolerance develops rapidly upon chronic administration — food intake returns to baseline within 8–12 days despite continued dosing — substantially limiting MC4R-directed appetite suppression as a therapeutic strategy for chronic obesity
• Spontaneous erections: A well-documented and frequently reported adverse effect; unpredictable erections occurring outside of sexual context represent a significant tolerability concern, particularly at higher doses

MC3R: Metabolic Regulation and Energy Homeostasis

• MC3R, expressed in the hypothalamus and limbic system, plays a modulatory role in energy balance and feeding behavior — distinct from but complementary to MC4R’s appetite effects
• Preclinical evidence suggests MC3R agonism may influence leptin sensitivity and the efficiency of energy expenditure, though human mechanistic data specific to Melanotan II’s MC3R component remain limited
• The MC3R contribution likely underlies some of the metabolic effects observed with Melanotan II use beyond simple appetite suppression

MC5R: Exocrine and Peripheral Effects

• MC5R is expressed in exocrine glands (sebaceous, lacrimal, salivary) and various peripheral tissues
• MC5R agonism by Melanotan II contributes to effects on sebaceous gland activity and may account for acne flares reported by users in the unregulated market
• Yawning and stretching — consistently reported side effects in human trials — are attributed in part to central and peripheral MC5R and MC4R co-activation

Structural Pharmacology and Metabolic Stability

• The lactam cyclization between Asp(2) and Lys(7) confers proteolytic stability beyond linear α-MSH analogues, supporting subcutaneous absorption and systemic activity
• Molecular formula: C₅₀H₆₉N₁₅O₉; molecular weight: 18 g/mol
• Plasma half-life is estimated in the range of 1–2 hours for the intact cyclic peptide — significantly longer than endogenous α-MSH (minutes) but short relative to lipidated or PEGylated analogues
• The D-Phe substitution at position 4 — retained from α-MSH optimization work — is critical for GPCR binding affinity and contributes to the cyclic peptide’s resistance to exopeptidase cleavage
• In vivo, Melanotan II undergoes hydrolysis to form bremelanotide (PT-141) via N-terminal deacetylation — a metabolite that retains significant MC4R activity, accounting for some of the prolonged sexual and CNS effects observed clinically beyond the parent compound’s plasma half-life

Melanotan II has a clinical evidence base concentrated in two areas: (1) the original tanning and melanogenesis indication from the University of Arizona development program (Phase 1–2, 1990s–2000s), and (2) sexual function — specifically erectile dysfunction and female sexual arousal — where two published RCTs provide Phase 2-level evidence. The therapeutic development of Melanotan II was not advanced to Phase 3 for any indication; instead, the more selective derivative bremelanotide was progressed for HSDD and ultimately FDA-approved. The available evidence is therefore adequate to characterize pharmacological activity, dose-response, and short-term tolerability, but insufficient by modern regulatory standards to support approval in the US or EU.

Preclinical and Structural Evidence

• Melanotan II emerged from a systematic structure-activity relationship (SAR) program at the University of Arizona in the 1980s–1990s, aimed at designing a metabolically stable, potent α-MSH analogue capable of producing melanogenesis without continuous UV exposure
• The cyclic lactam bridge was the key structural innovation — demonstrating in animal models that cyclization produced substantially greater receptor binding affinity and potency than linear α-MSH analogues, including Melanotan I
• Preclinical studies confirmed dose-dependent melanogenesis across species, validated the MC4R mechanism for erectile function in rodent and primate models, and identified the appetite-suppressing effects of central MC4R/MC3R activation
• Structure-function studies (Journal of Medicinal Chemistry; Biochemistry) characterized the Ac-Nle, D-Phe, and cyclic architecture as the pharmacophore responsible for high-affinity, non-selective MCR binding, providing the mechanistic foundation for all subsequent clinical work

Phase 1 Tanning and Safety Trial (University of Arizona, 1996)

Dorr et al. (Life Sciences, 1996) conducted the first published pilot Phase 1 human clinical study of Melanotan II:

• Healthy volunteers received five subcutaneous doses every other day at 0.025 mg/kg, establishing the pilot dosing regimen
• Visually apparent skin tanning was observed within the five-dose course — the first human demonstration of UV-independent melanogenesis via a synthetic melanotropic peptide
• Spontaneous penile erections were reported as an incidental adverse effect during this tanning-focused trial — the serendipitous observation that reoriented subsequent clinical development toward the sexual function indication
• Nausea and facial flushing were the primary adverse effects; the 0.025 mg/kg dose was recommended for future Phase 1 investigations based on the tolerability profile
• The tanning development program was subsequently deprioritized in favor of the sexual function and erection indication given the unexpected MC4R pharmacology revealed

Phase 2 Erectile Dysfunction Trials (University of Arizona, 1998–2000)

Wessells et al. (Journal of Urology, 1998) conducted the pivotal Phase 2 double-blind, placebo-controlled trial of Melanotan II in men with psychogenic erectile dysfunction:

• 10 men received a single subcutaneous dose of Melanotan II (0.025 mg/kg) or placebo in a crossover design; clinically apparent erections developed in 8 of 10 treated subjects none with placebo
• Mean duration of tip rigidity >80% was 38 minutes with Melanotan II vs. 3 minutes with placebo (p=0.0045)
• Transient side effects — nausea, stretching and yawning, decreased appetite — were reported more frequently with Melanotan II but none required treatment; the 0.025 mg/kg dose was characterized as having manageable side effects

Wessells et al. (International Journal of Impotence Research, 2000) followed with a broader evaluation in men with both psychogenic and organic erectile dysfunction:

• In the absence of sexual stimulation, erection occurred in 17 of 20 men; mean Rigiscan tip rigidity >80% was sustained for ~41 minutes
• Increased sexual desire was reported in 68% of Melanotan II doses vs. 19% of placebo doses (p<0.01)
• Nausea occurred in 12.9% of subjects at a severe rating with 0.025 mg/kg dosing — flagging the GI tolerability ceiling for the compound at the effective dose
• These findings directly stimulated the development of bremelanotide (PT-141) as a derived compound with a refined tolerability profile — ultimately the path to FDA approval of Vyleesi (2019)

Evidence in Female Sexual Dysfunction

• Preclinical and early-phase human data confirmed that Melanotan II stimulates sexual arousal and genital blood flow in women via the same central MC4R mechanism demonstrated in men, leading to early female HSDD/FSAD research interest
• Formal Phase 2 data in women were limited; the sexual function development path was pursued more rigorously for bremelanotide (PT-141), which received FDA approval for HSDD in premenopausal women

Evidence Summary by Indication

Clinical Development

No active sponsored clinical development program for Melanotan II as a therapeutic agent exists in the United States or EU as of May 2026:

• The sexual function and erectile dysfunction development path terminated when bremelanotide (PT-141) was pursued as a more refined successor compound; bremelanotide received FDA approval in 2019 as Vyleesi for HSDD in premenopausal women — the only FDA-approved therapeutic to emerge from the Melanotan II pharmacological lineage
• The tanning development program was halted following recognition of the safety concerns associated with non-selective MCR activation and the mole/nevi darkening risk, combined with the development of the more selective afamelanotide (Melanotan I/Scenesse), which received FDA approval in 2019 for erythropoietic protoporphyria
• A Phase 2 trial evaluating Melanotan II as an adjunct to NB-UVB phototherapy was registered on gov as of February 2026 (NCT07437560), representing a limited contemporary research interest in the compound’s melanogenic activity for specific dermatological applications
• No NDA, BLA, or formal IND for broad therapeutic development of Melanotan II is on file with the FDA

Regulatory Status

FDA (United States): Melanotan II is not approved for any human therapeutic or cosmetic use in the United States:

• Melanotan II was placed on the FDA’s Category 2 bulk drug substance list in September 2023, alongside GHRP-2 and seventeen other peptides, citing safety concerns that preclude its use in compounding under Section 503A or 503B of the FD&C Act
• In April 2026, the FDA announced its intent to remove Melanotan II from the Category 2 list as part of a group of twelve peptides (alongside BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, MOTs-C, Semax, and TB-500); the formal PCAC review is scheduled for July 23–24, 2026
• Critically: removal from the Category 2 list does not constitute approval for compounding. Substances must separately meet eligibility criteria under 503A or 503B — including listing on the Category 1 eligible substances list, a USP/NF monograph, or status as a component of an FDA-approved drug product. Melanotan II meets none of these criteria as of May 2026; its compounding status post-PCAC review is therefore uncertain
• The FDA has issued explicit warnings to consumers against purchasing Melanotan II products sold online or labeled “for research purposes” or “not for human consumption,” noting that no manufacturer has completed the testing required for FDA approval
• Melanotan II is not a component of any FDA-approved drug product; it is not listed in USP or NF monographs

WADA (Anti-Doping): Melanotan II is prohibited in competitive sport under Section S0 (Non-Approved Substances) of the WADA Prohibited List — the broadest prohibition category, covering any pharmacological substance not approved by a governmental regulatory authority for human therapeutic use:

• The 2026 WADA Prohibited List, effective January 1, 2026, maintains Melanotan II’s prohibition under S0
• S0 prohibits all pharmacological substances not approved for human therapeutic use in any jurisdiction globally for sport purposes — a classification that applies regardless of the athlete’s intent or claimed medical need
• No therapeutic use exemption (TUE) pathway exists for Melanotan II given its non-approved status in all jurisdictions; any athlete using Melanotan II for any purpose faces a potential anti-doping rule violation

International:

• EMA (European Union): Not approved for any indication. Afamelanotide (Melanotan I/Scenesse) holds EMA approval for erythropoietic protoporphyria — Melanotan II does not
• TGA (Australia): Not approved for sale or use as a tanning agent or any therapeutic indication. The TGA has explicitly stated that advertising and supplying Melanotan II to the public is illegal; restrictions apply across all formulations (injection, nasal spray, tablet, cream). The TGA has coordinated with social media platforms to remove Melanotan-II advertising
• Health Canada: Not approved; no authorized product status
• Japan (PMDA): Not approved for any indication
• Melanotan II’s global availability outside of the one registered clinical trial (NCT07437560) is limited to unregulated research chemical vendors and internet-based suppliers, none of which operate under cGMP oversight

Melanotan II’s safety data derives from the University of Arizona Phase 1 (1996) and Phase 2 erectile dysfunction trials (1998, 2000), supplemented by post-market case reports, dermatology case series, and regulatory safety reviews from the FDA (2023 Category 2 determination), TGA (Australia), and multiple national health authorities. The overall clinical trial safety profile at Phase 1–2 doses characterizes Melanotan II as having dose-limiting GI toxicity (nausea) and predictable, mechanism-based adverse effects across multiple organ systems — reflecting the broad receptor activation profile. Longer-term and post-market data from unregulated use consistently raises serious dermatological and oncological safety signals that the controlled trial database, conducted over short durations with limited participant numbers, could not adequately characterize.

Established Adverse Effects from Clinical Trials

Adverse effects are dose-dependent and directly attributable to non-selective MCR activation:

• Nausea: The most dose-limiting adverse effect; reported in the majority of subjects across Phase 1–2 trials. At 0.025 mg/kg, 12.9% of subjects experienced severe nausea — establishing the GI tolerability ceiling that contributed to the shift toward bremelanotide development
• Stretching and yawning: Reported in 56% of subjects across trial data; attributed to central MC4R and MC5R co-activation; a class-effect of non-selective melanocortin agonism at CNS receptors
• Spontaneous penile erections: Well-documented, mechanism-driven, and clinically unpredictable; erections occurred without sexual stimulation in 85–90% of male subjects in ED trials and are a consistent adverse effect at effective doses
• Facial flushing: Reported acutely post-injection, consistent with peripheral vasodilatory effects of melanocortin receptor activation
• Decreased appetite: Consistent with central MC4R anorexigenic signaling; short-term but dose-dependent
• Fatigue and sedation: Reported across clinical trial subjects, likely attributable to central MC4R modulation
• Acne and skin changes: Consistent with MC5R agonism on sebaceous glands; reported in uncontrolled post-market use

Potential Serious Adverse Effects

Serious adverse effects identified through case reports, regulatory reviews, and dermatological surveillance:

• Mole/nevi darkening and proliferation: The most widely reported and clinically concerning dermatological effect. Case reports document rapid darkening and size increase of pre-existing melanocytic nevi within days of Melanotan II use — a direct consequence of MC1R-driven melanocyte stimulation in nevi. Multiple national dermatology organizations and the TGA, FDA, and UNSW have issued formal warnings regarding this signal
• Melanoma risk: A serious, unresolved safety question. Case reports have described melanomas arising from or associated with Melanotan II use. A 2013 systematic review found no conclusive evidence of causation; a 2021 review concluded that the elevated melanoma signal in Melanotan users is “probably explained by more UV exposure” among users who combine the drug with tanning bed use. However, the possibility of direct MC1R-driven promotion of malignant transformation in dysplastic nevi cannot be excluded without adequately powered long-term safety data
• Priapism: Prolonged, painful erection constituting a urological emergency — reported in case literature following Melanotan II use; directly attributable to the MC4R-driven erectile mechanism operating without the physiological off-switches governing endogenous erection
• Renal infarction: Reported in case literature; mechanism not fully characterized; may reflect vascular effects of supra-physiological melanocortin receptor activation
• Rhabdomyolysis: Reported; clinical context and causal mechanism under investigation
• Encephalopathy syndrome: Reported case; neurological mechanism plausible given central MC4R/MC3R expression
• Pancreatitis: Reported; mechanism unclear
• Melanonychia (abnormal nail darkening): Consistent with systemic MC1R-driven pigmentary effects extending beyond skin

Manufacturing Quality in the Unregulated Market

• No cGMP manufacturing oversight applies to any commercially available Melanotan II product; contamination with residual TFA, heavy metals, endotoxins, and microbial load represent serious injection safety risks for the overwhelming majority of Melanotan II currently in consumer circulation
• Product identity and potency cannot be verified; mislabeling, underdosing, overdosing, and substitution with structurally similar but distinct peptides are documented risks across the unregulated peptide market
• The FDA, TGA, and multiple European health agencies have explicitly warned consumers against purchasing Melanotan II from online vendors; the TGA has characterized Melanotan II as a product whose development as a potential medicine was halted due to safety reasons
• Multiple national health organizations have issued formal safety warnings regarding the unregulated use of Melanotan I and II in the academic literature (International Journal of Dermatology, 2017)

1. Dorr RT, et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784. https://doi.org/10.1016/0024-3205(96)00160-9
2. Wessells H, et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389–393. https://pubmed.ncbi.nlm.nih.gov/9679884/
3. Wessells H, et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II. International Journal of Impotence Research, 12(Suppl 4), S74–S79. https://www.nature.com/articles/3900582
4. Jonsson S, et al. (2002). Activation of the central melanocortin system chronically reduces body weight without the development of tolerance. American Journal of Physiology — Regulatory, Integrative and Comparative Physiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC5572812/
5. Hadley ME & Dorr RT. (2006). Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930.
6. DermNet NZ. (2023). Melanotan II. https://dermnetnz.org/topics/melanotan-ii
7. Westlake Dermatology. (2026). Melanotan II (“Tan Jabs”): Why They’re Not Worth the Risk. https://www.westlakedermatology.com/trends/melanotan-II/
8. S. Food and Drug Administration. (2023). Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — Category 2: Melanotan II. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
9. Amanecia Health / SSRP Institute. (2026, April). FDA Announces Change in Status of 12 Peptides — Melanotan II among those proposed for Category 2 removal. https://ssrpinstitute.org/news/fda-announces-change-in-status-of-12-peptides/
10. World Anti-Doping Agency. (2025). 2026 WADA Prohibited List, S0 Non-Approved Substances (effective January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
11. Therapeutics Goods Administration (TGA), Australia. (2025). Don’t risk using tanning products containing melanotan. https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan
12. Braz JM, et al. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 56(10), 975–980. https://onlinelibrary.wiley.com/doi/10.1111/ijd.13585
13. gov. (2026). Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy. NCT07437560. https://clinicaltrials.gov/study/NCT07437560